<span item_type="fundamental" item_id="6afc2cd3641fad7401580f9485045346" counter_id="ST/US/NXPLW" env="prod"></span><span item_type="announcement" item_id="516398055071224961" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 14.53 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.05.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -1.485 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Consolidated Revenue</strong>: $14.5 million for Q1 2025, down from $17.5 million in Q1 2024, primarily due to declines in Healthcare Operations and prescription volume.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit Margin</strong>: Overall gross profit margin decreased to 23.8% from 27.8% YoY. Healthcare segment margin decreased to 23.8% from 27.7%, and e-Commerce Operations margin decreased to 24.1% from 28.1%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li><li><strong>Operating Expenses</strong>: Decreased by 26.2% to $4.9 million from $6.7 million YoY, attributed to the elimination of non-recurring expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li><li><strong>Net Loss</strong>: Net loss attributable to NextPlat Corp common shareholders decreased by 9% to $1.3 million, or - $0.05 per diluted share, compared to $1.5 million, or - $0.08 per diluted share in Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Cash Position</strong>: The company ended the quarter with $17.7 million in cash.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Recurring Airtime Revenue</strong>: Increased by 51% to record levels, driven by new connectivity contracts and expanded communications capabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>NextPlat Corp is focusing on expanding its service base with new 340B pharmacy service agreements to drive revenue growth and improve margins. The company is also exploring strategic alternatives to diversify its Healthcare Operations and enhance top-line growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925017081/ex_770189.htm"></span></li></ul>

NEXTPLAT CORP C/WTS 02/06/2027 (TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 14.53 M